K Hospital informs about Russian cancer treatment drug, expected price 18 million VND/bottle

In response to information about the circulation of the Russian-made cancer treatment drug Pembroria, K Hospital said it is planning to purchase the drug to use for patients in the near future.

Pembroria made in Russia

On November 13, K Hospital had information related to drugs containing the active ingredient pembrolizumab that are currently being used to treat cancer patients.

Estimated price 18 million VND/bottle

Accordingly, on October 31, 2025, the Drug Administration of Vietnam, Ministry of Health, granted a circulation registration certificate for the drug Pembroria with the active ingredient pembrolizumab, 100mg/4ml vial manufactured by Limited Liability Company "PK-137", Russian Federation.

Pembroria is a biological drug with the same active ingredient as Keytruda, which has been licensed by the Ministry of Health for circulation in Vietnam since 2017.

Pembroria is approved for the indications melanoma, non-small cell lung carcinoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, esophageal carcinoma, and cancers with microsatellite instability-high (MSI-H) or mismatch repair defects.

The drug is also approved for the treatment of cervical cancer, renal cell carcinoma, endometrial carcinoma, triple-negative breast cancer, adenocarcinoma of the stomach or gastroesophageal junction, and cholangiocarcinoma.

The expected price of Pembroria is about 18 million VND/bottle, with the usual dose being 2 bottles for 1 treatment cycle.

"Thus, the cost for a patient's treatment cycle is about 36 million VND with a dose of 200mg (2 bottles). Currently, K Hospital is planning to purchase Pembroria medicine to use for patients in the near future.

Not all patients with the cancers listed above will be candidates for pembrolizumab.

The use of pembrolizumab also depends on many factors such as the patient's condition, tumor mutation type, disease stage... assessed by oncologists," informed K Hospital.

The drug with the same active ingredient has been available in Vietnam since 2017.

Also according to the hospital, Pembrolizumab is the name of the active ingredient (active ingredient) invented by the US company MSD with the trade name Keytruda, 100mg/4ml bottle.

Pembrolizumab is a monoclonal antibody against PD-1 and is a biologic drug indicated for certain types of cancer, belonging to the group of immunotherapy. The drug is administered by intravenous infusion at a medical facility.

Currently, Keytruda is approved by the Ministry of Health for 14 indications including malignant melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, urothelial carcinoma, head and neck squamous cell carcinoma, gastric cancer, cancer with high-grade microsatellite instability, cervical cancer, hepatocellular carcinoma, colorectal cancer with high-grade microsatellite instability or mismatch repair defect, primary mediastinal large B-cell lymphoma, esophageal cancer, triple-negative breast cancer, renal cell carcinoma.

The current price of Keytruda is about 62 million VND/bottle.

The drug has a partial free support program for eligible cancer patients according to the decision of the Ministry of Health.

The above support program is being implemented at K Hospital and many other hospitals nationwide. With this program, the maximum cost for a patient's treatment cycle is about 62 million VND with a dose of 200mg (2 bottles) and some cycles can be completely free, depending on the level of support the patient is approved for.

At K Hospital, treatment will be individualized for each patient. Based on many factors, the doctor will advise and provide a suitable treatment regimen to ensure effective treatment for the patient.

Back to topic

WILLOW

Source: https://tuoitre.vn/benh-vien-k-thong-tin-ve-thuoc-dieu-tri-ung-thu-nga-du-kien-gia-18-trieu-dong-lo-20251113193326201.htm